| miR-155 may function as a tumor suppressor to regulate gastric cancer cell metastasis by targeting SMAD2, and its downregulation in gastric cancer cells may be partly ascribed to DNA methylation. | gastric, |
| Tumor suppressive microRNA mediated cancer pathways inhibit cell migration and invasion in renal cell carcioma. | kidney, |
| The data indicate an oncogenic role for miR-155 in B-cell lymphoma which involves targeting the tumor suppressor NIAM. | lymphoma, |
| Results showed an upregulation of CCAT1 detected in adult acute myeloid leukemia (AML) patients. It repressed monocytic differentiation and promoted cell growth by sequestering tumor suppressive miR-155 which expression significantly decrease in AML patients but increases c-myc expression. | leukemia, |
| MicroRNA-155 acts as a tumor suppressor in colorectal cancer by targeting CTHRC1 in vitro | colorectal, |
| The tumor suppressor role of miR-155-5p in gastric cancer | gastric, |
| MiR-155-3p acts as a tumor suppressor and reverses paclitaxel resistance via negative regulation of MYD88 in human breast cancer | breast, |
| experiments indicate that miR-155 can act as a tumor suppressor by reducing potentially oncogenic translocations generated by activation-induced cytidine deaminase | None |
| miR-155-3p might be a novel tumor suppressive microRNA silenced in MCL due to promoter hypermethylation of its host gene MIR155HG, resulting in upregulation of LT-beta. | None |
| Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. | pancreatic, |
| study provides the first evidence for an oncogenic activity of miR-155, miR-203, miR-210 and miR-222 in the development of pancreatic cancer as has been reported for other tumor types | pancreatic, |
| Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. | lymphoma, |
| Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. | lymphoma, |
| MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. | breast, |
| MicroRNA-155 is a candidate oncogenic microRNA and plays an important role in promoting HCC cells invasion. Findings suggest that microRNA-155 may serve as a novel biomarker for tumor recurrence and survival of HCC patients following OLT. | liver, |
| MiR-155 is a liposarcoma oncogene that targets casein kinase-1alpha and enhances beta-catenin signaling. | sarcoma, |
| Review examines role of miR-155 in breast cancer progression. The collated data of target genes and biologic pathways of miR-155 identified in this review suggest new avenues of research for this oncogenic miRNA. | breast, |
| Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation | oral |
| Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implications for cancer therapeutics. | oral |
| miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Emu-miR-155 transgenic mouse model. | lymphoma, |